Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
Author Information
Author(s): Mormando Marilda, Lauretta Rosa, Puliani Giulia, Bianchini Marta, Spoltore Maria Elena, Appetecchia Marialuisa
Primary Institution: IRCCS Regina Elena National Cancer Institute
Hypothesis
What are the treatment responses and adverse events in patients with metastatic medullary thyroid cancer treated with multiple tyrosine kinase inhibitors?
Conclusion
The best management of metastatic medullary thyroid cancer relies on an individualized approach to minimize treatment withdrawal due to toxicity.
Supporting Evidence
- Three patients obtained a partial response to treatment.
- Two patients achieved disease stability.
- Adverse events included non-neoplastic ascites and lung cavitations.
Takeaway
This study looked at five patients with a rare type of thyroid cancer and how they responded to different treatments. Some got better, but others had side effects that made it hard to keep taking their medicine.
Methodology
Five patients with metastatic medullary thyroid cancer were retrospectively selected and treated with at least two different tyrosine kinase inhibitors.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the small sample size.
Limitations
The study is based on a small cohort of patients, limiting the generalizability of the findings.
Participant Demographics
Five patients with metastatic medullary thyroid cancer, varying in age and treatment history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website